EGFR and hepatocellular carcinoma: Therefore, we attempted to predict the response to targeted therapy in high- and low-risk patients and found that high-risk patients with HCC were more sensitive to pazopanib (VEGFR inhibitor), dasatinib (Src/Bcr-Abl inhibitor), erlotinib, and gefitinib (EGFR inhibitor) than low-risk patients were.